Clin2
NCT06850597Possibly a fitRecruiting

Testing dimethyl fumarate for early Alzheimer's disease

MCIMCI-AD, Early Stage Alzheimer's DiseaseAlzheimer's Disease

Treatments studied

Part of Brain & nervous system, Mental health clinical trials.

This study tests a drug called dimethyl fumarate to see if it can help people with early Alzheimer's disease. It may slow down memory loss and thinking problems.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 2
Enrollment
30 people
Ages
55 years to 90 years
Study type
Interventional

Who can take part

  • You are between 55 and 90 years old.
  • You have been diagnosed with mild cognitive impairment or mild to moderate dementia due to Alzheimer's disease.
  • You have a family member or friend who can help you during the study.
  • You have at least 6 years of education.
  • If you take Alzheimer's medications, you must be on a stable dose for at least 3 months before starting the study.
  • You must not have other serious health problems like liver or kidney disease, or a history of stroke.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06489548Recruiting· Phase 2
Foralumab for Early Alzheimer's Disease

This study tests an experimental drug called Foralumab, which aims to calm overactive immune cells in the brain linked to Alzheimer's. It may help slow memory loss in people with early-stage Alzheimer's.

Boston, Massachusetts
NCT07094516Recruiting· Phase 2
Testing VHB937 for early Alzheimer's disease

This trial tests a new medicine, VHB937, in people with early Alzheimer's (mild cognitive impairment or mild dementia). The goal is to see if it can slow down memory loss and thinking problems.

Phoenix, Arizona
NCT07781657Not yet recruiting· Phase 2
Testing an experimental drug for early Alzheimer's disease

This study tests an experimental medication called RO7568282 to see if it can slow down memory decline in people with early Alzheimer's disease. If you have early memory problems and a confirmed Alzheimer's-related brain change, you may be able to join.

NCT07688213Recruiting· Phase 2
Study of an investigational drug for early Alzheimer's disease

This trial tests an investigational injection for people in the early stages of Alzheimer's. It aims to see if the drug can safely slow down memory loss and brain changes.

The Villages, Florida
NCT07234942Recruiting· Phase 1
Safety study of RO7812653 for early Alzheimer's disease

This trial tests a new drug, RO7812653, in people with early symptomatic Alzheimer's disease (including mild cognitive impairment due to AD). The goal is to see if it is safe and how the body handles it.

Toronto, Ontario
NCT06362707Recruiting· Phase 2
Fasudil trial for early Alzheimer's disease

This trial tests a medication called fasudil to see if it can help people with early Alzheimer's disease. It is for people who have early symptoms (mild cognitive impairment or mild dementia) and have biomarker evidence of Alzheimer's in their brain.

Tromsø, Nordland

Hear when a new MCI trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.